euro-infectious-diseases-histopathology-2018-posters

25 / 33

Volume 4 Journal of Infectious Diseases and Treatment
ISSN: 2472-1093
Page 61
Euro Infectious Diseases 2018 &
Histopathology 2018
September 27-29, 2018
&
JOINT EVENT
September 27-29, 2018 Rome, Italy
5th International Conference on Histopathology & Cytopathology
10th Euro-Global Conference on Infectious Diseases
AStudy on the Prevalence ofAdverseOcularManifestations inPediatric Patients ReceivingEthambutol
in the Revised National Tuberculosis Control Program at East Avenue Medical Center and District II
Health Centers in Quezon City
Anna Sophia R. Lim and Kristine G. Pormida
East Avenue Medical Center, Philippines
Tuberculosis is one of the most important systemic infections throughout the world. Ethambutol has been used to treat
tuberculosis since the 1960s, but the related visual impairment was recognized soon after its introduction. Objective of
the study is to determine the prevalence of adverse ocular manifestations after taking Ethambutol as part of the treatment
regimen of children with Tuberculosis. This is a cross – sectional analytical study. Patients aged 3 – 18 years old enrolled for
treatment of tuberculosis at the TB DOTS facility of East Avenue Medical Center and District II Health Centers in Quezon City
were included in the study. Patients without prior diagnosis of any opthalmologic problems and without history of previous
ophthalmologic signs and symptoms were included. Pertinent demographic factors, personal and medical history of patients
were obtained. Visual acuity by Snellen chart, color vision by the Ishihara Chart, direct fundoscopic examination, and anterior
segment slit-lamp biomicroscopy were performed. Statistical analysis used were Mann Whitney U Test, Yates’ chi-square test,
Fisher’s Exact test, Chi-square test. Statistical significance was based on p-values ≤ 0.05. Results: 93 out of 101 patients had
no ocular manifestations, however, 8 (7.9%) of the subjects had ophthalmologic findings; 1 had red-green color vision defect,
6 with error of refraction, and 1 had blurring of superior disc margin in both eyes with red-green color vision defect. There
was no significant relationship on the dosage and duration of the drug to the manifestation of optic symptoms of the patients.
Study showed that there was no significant ophthalmologic effect on children taking ethambutol provided that the drug will
be given within the recommended dose and duration. Patients however, should be monitored for any visual manifestations
during treatment.
J Infec Dis Treat 2018, Volume 4
DOI: 10.21767/2472-1093-C1-003